MedTrace Logo

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

NCT01012362 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2017-12-28

Study results available
· View outcomes & findings →

Summary

This is a Phase I study; dose escalating the combination of pazopanib when taken daily and ixabepilone when administered on day 1 of a 3 week treatment course.

Conditions

Interventions

DRUG

Pazopanib

Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.

DRUG

Ixabepilone

Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Masonic Cancer Center, University of Minnesota

    lead OTHER

Principal Investigators

  • Arkaduisz Z Dudek, MD · Masonic Cancer Center, University of Minnesota

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01012362 on ClinicalTrials.gov